Medwire News: Virtual CHIEF-HF Trial Supports Canagliflozin in Heart Failure

The virtual CHIEF-HF trial has demonstrated a significant positive effect of canagliflozin on heart failure (HF) symptoms without the need for in-person clinic visits, the investigators report in Nature Medicine.

The benefits occurred regardless of whether people had a reduced or preserved ejection fraction and whether or not they had diabetes, said John Spertus, MD, Saint Luke’s Mid America Heart Institute, and co-researchers.

The study was designed to determine if sodium-glucose cotransporter 2 inhibition could improve HF symptom burden, which the team notes “is a critical goal for HF management.”

Read the full Medwire News article: Virtual CHIEF-HF Trial Supports Canagliflozin in Heart Failure

Related Content

Medscape logo
Nov. 17, 2021

Medscape: Canagliflozin Improves HF Symptoms in Fully Remote Trial
New research reported at the AHA Scientific Sessions 2021 shows that the benefits of sodium-glucose cotransporter-2 (SGLT2) inhibitors on symptoms and quality of life in patients with heart failure extend to canagliflozin.
Nov. 17, 2021

TCTMD: Canagliflozin Improves Quality of Life in HF Patients
Treating heart failure patients with canagliflozin significantly improves quality of life, with the marked benefit observed early and sustained through follow-up, according to the results of the CHIEF-HF trial.
""
Sep. 14, 2020

New Clinical Trial for Heart Failure Tests Patients Remotely Using Wearable Devices
The world's first decentralized, digitally driven medical study has patients wear smart watches to record the effects of a heart failure medication.